Nomura Holdings’s Aclaris Therapeutics ACRS Stock Holding History

Nomura Holdings’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,068	Closed	-$190K	–	1938
2021 Q4	$190K	Sell	13,068 -49,365	-79%	-$748K	﹤0.01%	1848
2021 Q3	$1.09M	Sell	62,433 -177,800	-74%	-$2.85M	﹤0.01%	1096
2021 Q2	$4.22M	Hold	240,233	–	–	0.01%	626
2021 Q1	$6.05M	Buy	+240,233	New	+$4.7M	0.01%	488

Other funds holding ACRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Nomura Holdings's ACRS Position: Q1 2022 in Review

Nomura Holdings sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 13,068 shares — an estimated $190K sold.

Nomura Holdings first reported a position in ACRS in Q1 2021 and held it in 4 quarters. The position peaked at $6.05M in Q1 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

Nomura Holdings reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
Nomura Holdings sold 13,068 Aclaris Therapeutics shares in Q1 2022, an estimated $190K.
Nomura Holdings first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 4 quarters.
Nomura Holdings's Aclaris Therapeutics position peaked at $6.05M in Q1 2021.
109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Nomura Holdings's 13F filing for Q1 2022, filed 18 May 2022.